K Dane Wittrup

List of Publications by Year in Descending Order

187 papers	13,262 citations	62 h-index	111 g-index
195 ext. papers	15,119 ext. citations	9.1 avg, IF	6.51 L-index

#	Paper	IF	Citations
187	Maximizing response to intratumoral immunotherapy in mice by tuning local retention.. *Nature Communications*, **2022**, 13, 109	17.4	4
186	Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.. *Nature Biomedical Engineering*, **2022**,	19	5
185	Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation.. *Methods in Molecular Biology*, **2022**, 2491, 29-62	1.4	
184	Type I interferon activates MHC class I-dressed CD11b conventional dendritic cells to promote protective anti-tumor CD8 T cell immunity. *Immunity*, **2021**,	32.3	16
183	Lack of CD8 T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. *Science Immunology*, **2021**, 6, eabi8800	28	5
182	Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. *PLoS ONE*, **2021**, 16, e0248903	3.7	0
181	High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. *Nature Communications*, **2021**, 12, 773	17.4	10
180	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. *Nature Biomedical Engineering*, **2020**, 4, 636-648	19	23
179	Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. *Nature Cancer*, **2020**, 1, 882-893	15.4	38
178	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and Y-DOTA. *Molecular Cancer Therapeutics*, **2020**, 19, 2575-2584	6.1	4
177	Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. *MAbs*, **2019**, 11, 803-808	6.6	4
176	Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. *Frontiers in Oncology*, **2019**, 9, 330	5.3	7
175	Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. *OncoImmunology*, **2019**, 8, e1558678	7.2	7
174	Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. *Science Translational Medicine*, **2019**, 11,	17.5	79
173	Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. *Science*, **2019**, 365, 162-168	33.3	148
172	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. *Trends in Immunology*, **2019**, 40, 12-21	14.4	40
171	Detection of amyloid oligomers toward early diagnosis of Alzheimer's disease. *Analytical Biochemistry*, **2019**, 566, 40-45	3.1	16

170	Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. *Nature Communications*, **2018**, 9, 1461	17.4	13
169	Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types. *Journal of Molecular Biology*, **2018**, 430, 1786-1798	6.5	6
168	A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. *Molecular Cancer Therapeutics*, **2018**, 17, 1773-1780	6.1	7
167	Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. *Journal of Molecular Biology*, **2018**, 430, 119-130	6.5	27
166	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. *Blood*, **2018**, 131, 611-620	2.2	37
165	Biophysical properties of the clinical-stage antibody landscape. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 944-949	11.5	259
164	Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. *Journal of Experimental Medicine*, **2017**, 214, 1679-1690	16.6	31
163	Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. *MAbs*, **2017**, 9, 257-268	6.6	10
162	Nonspecificity in a nonimmune human scFv repertoire. *MAbs*, **2017**, 9, 1029-1035	6.6	16
161	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. *Journal of Nuclear Medicine*, **2017**, 58, 1735-1742	8.9	28
160	Chaperone proteins as single component reagents to assess antibody nonspecificity. *MAbs*, **2017**, 9, 1036-1040	6.6	17
159	An engineered protein antagonist of K-Ras/B-Raf interaction. *Scientific Reports*, **2017**, 7, 5831	4.9	44
158	Antitumor Antibodies Can Drive Therapeutic T Cell Responses. *Trends in Cancer*, **2017**, 3, 615-620	12.5	21
157	Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. *Journal of Molecular Biology*, **2017**, 429, 2528-2541	6.5	9
156	Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. *Nucleic Acids Research*, **2017**, 45, 7602-7614	20.1	5
155	Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. *Journal of Clinical Investigation*, **2017**, 127, 2176-2191	15.9	171
154	Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. *Nature Medicine*, **2016**, 22, 1402-1410	50.5	302
153	Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools. *Journal of Molecular Biology*, **2016**, 428, 1272-1289	6.5	16

152	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 925-937	8.8	29
151	Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. *AAPS Journal*, **2016**, 18, 635-46	3.7	48
150	Temporally Programmed CD8+DC Activation Enhances Combination Cancer Immunotherapy. *Cell Reports*, **2016**, 17, 2503-2511	10.6	32
149	Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). *AAPS Journal*, **2016**, 18, 861-75	3.7	31
148	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. *Cancer Research*, **2016**, 76, 6669-6679	10.1	21
147	Target-independent variable region mediated effects on antibody clearance can be FcRn independent. *MAbs*, **2016**, 8, 1269-1275	6.6	24
146	Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. *Journal of Biological Chemistry*, **2016**, 291, 22496-22508	5.4	34
145	Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. *Journal of Molecular Biology*, **2016**, 428, 4228-4241	6.5	8
144	High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. *MAbs*, **2015**, 7, 770-7	6.6	52
143	Immunotherapy: The path to win the war on cancer?. *Cell*, **2015**, 161, 185-6	56.2	73
142	Antibody-mediated neutralization of perfringolysin o for intracellular protein delivery. *Molecular Pharmaceutics*, **2015**, 12, 1992-2000	5.6	10
141	Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 3320-5	11.5	71
140	Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. *Cancer Cell*, **2015**, 27, 489-501	24.3	114
139	Protein Engineering and Selection Using Yeast Surface Display. *Methods in Molecular Biology*, **2015**, 1319, 3-36	1.4	62
138	A switchable yeast display/secretion system. *Protein Engineering, Design and Selection*, **2015**, 28, 317-25	1.9	32
137	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. *Journal of Pharmaceutical Sciences*, **2015**, 104, 4409-4416	3.9	10
136	Molecular Magnetic Resonance Imaging of Tumor Response to Therapy. *Scientific Reports*, **2015**, 5, 14759	4.9	36
135	Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. *Cell*, **2015**, 160, 785-797	56.2	125

134	Five birds, one stone: neutralization of Ehemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. *MAbs*, **2015**, 7, 243-54	6.6	103
133	A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. *Blood*, **2015**, 126, 118-118	2.2	1
132	A graphene-based physiometer array for the analysis of single biological cells. *Scientific Reports*, **2014**, 4, 6865	4.9	29
131	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. *Integrative Biology (United Kingdom)*, **2014**, 6, 388-98	3.7	43
130	Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. *Analytical Biochemistry*, **2014**, 460, 9-15	3.1	5
129	A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e162	10.7	6
128	Tumor cells are dislodged into the pulmonary vein during lobectomy. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 148, 3224-31.e1-5	1.5	18
127	Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia. *Blood*, **2014**, 124, 3749-3749	2.2	2
126	Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. *Methods in Molecular Biology*, **2014**, 1131, 151-81	1.4	48
125	Emergent properties of nanosensor arrays: applications for monitoring IgG affinity distributions, weakly affined hypermannosylation, and colony selection for biomanufacturing. *ACS Nano*, **2013**, 7, 7472-82	16.7	38
124	Engineering fibronectin-based binding proteins by yeast surface display. *Methods in Enzymology*, **2013**, 523, 303-26	1.7	40
123	Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. *Protein Engineering, Design and Selection* , **2013**, 26, 663-70	1.9	95
122	Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. *Structure*, **2013**, 21, 1966-78	5.2	76
121	Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. *International Journal of Cancer*, **2013**, 133, 2925-33	7.5	13
120	Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles. *Biomacromolecules*, **2013**, 14, 1093-102	6.9	15
119	Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. *Cancer Research*, **2013**, 73, 1547-58	10.1	146
118	Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. *Journal of Molecular Biology*, **2013**, 425, 444-56	6.5	52
117	Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin. *Molecular Cancer Therapeutics*, **2013**, 12, 1774-82	6.1	21

116	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. *Protein Engineering, Design and Selection*, **2013**, 26, 187-93	1.9	26
115	CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate. *Cancer Immunology Research*, **2013**, 1, 393-401	12.5	
114	Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. *Journal of Pharmaceutical Sciences*, **2012**, 101, 860-7	3.9	32
113	Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. *Molecular Cancer Therapeutics*, **2012**, 11, 1365-72	6.1	33
112	A mechanistic compartmental model for total antibody uptake in tumors. *Journal of Theoretical Biology*, **2012**, 314, 57-68	2.3	65
111	Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. *Journal of Molecular Biology*, **2012**, 422, 532-44	6.5	27
110	Practical theoretic guidance for the design of tumor-targeting agents. *Methods in Enzymology*, **2012** , 503, 255-68	1.7	125
109	Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. *Protein Engineering, Design and Selection*, **2012**, 25, 47-57	1.9	22
108	Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. *Journal of Immunology*, **2012**, 189, 1708-16	5.3	29
107	Yeast Surface Display in Protein Engineering and Analysis **2011**, 621-648		1
106	Exploiting bias in a non-immune human antibody library to predict antigenicity. *Protein Engineering, Design and Selection*, **2011**, 24, 845-53	1.9	1
105	A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. *Journal of Molecular Biology*, **2011**, 414, 337-55	6.5	31
104	Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. *Nuclear Medicine and Biology*, **2011**, 38, 223-33	2.1	44
103	Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. *Journal of Biological Chemistry*, **2011**, 286, 41273-41285	5.4	75
102	Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. *Molecular Imaging and Biology*, **2011**, 13, 215-21	3.8	20
101	Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination. *Molecular Biotechnology*, **2011**, 47, 57-69	3	12
100	Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. *Journal of Biological Chemistry*, **2011**, 286, 4165-72	5.4	58
99	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 13252-7	11.5	118

98	A modular IgG-scFv bispecific antibody topology. *Protein Engineering, Design and Selection*, **2010**, 23, 221-8	1.9	78
97	The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. *Protein Engineering, Design and Selection*, **2010**, 23, 211-9	1.9	29
96	Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. *Journal of Immunology*, **2010**, 184, 3394-400	5.3	12
95	Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. *Journal of Immunology*, **2010**, 184, 5954-8	5.3	17
94	Stability and CDR composition biases enrich binder functionality landscapes. *Journal of Molecular Biology*, **2010**, 401, 84-96	6.5	67
93	Yeast Display and Selections **2010**, 207-233		7
92	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 5082-7	11.5	55
91	A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. *Molecular Cancer Therapeutics*, **2009**, 8, 2861-71	6.1	411
90	Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. *Journal of Immunology*, **2009**, 182, 1541-7	5.3	113
89	Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. *Biotechnology and Bioengineering*, **2009**, 103, 1192-201	4.9	144
88	Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display. *Biotechnology Progress*, **2009**, 25, 774-83	2.8	62
87	High-affinity lamprey VLRA and VLRB monoclonal antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12891-6	11.5	96
86	Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. *Journal of Immunotherapy*, **2009**, 32, 887-94	5	31
85	Monovalent, reduced-size quantum dots for imaging receptors on living cells. *Nature Methods*, **2008**, 5, 397-9	21.6	365
84	Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. *Journal of Molecular Biology*, **2008**, 381, 1238-52	6.5	139
83	Factors determining antibody distribution in tumors. *Trends in Pharmacological Sciences*, **2008**, 29, 57-61	13.2	156
82	Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17694-9	11.5	42
81	Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. *Cancer Research*, **2008**, 68, 3334-41	10.1	85

80	Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20167-72	11.5	144
79	Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. *Journal of Immunology*, **2008**, 180, 1576-83	5.3	39
78	Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. *Molecular Cancer Therapeutics*, **2008**, 7, 2233-40	6.1	85
77	Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13003-8	11.5	63
76	Inducing efficient cross-priming using antigen-coated yeast particles. *Journal of Immunotherapy*, **2008**, 31, 607-19	5	13
75	A33 antigen displays persistent surface expression. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1017-27	7.4	53
74	Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1879-90	7.4	59
73	Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. *Advanced Drug Delivery Reviews*, **2008**, 60, 1421-34	18.5	375
72	Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. *Biotechnology and Bioengineering*, **2007**, 97, 1009-20	4.9	56
71	Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display. *Chemistry and Biology*, **2007**, 14, 1176-85		81
70	Computational design of antibody-affinity improvement beyond in vivo maturation. *Nature Biotechnology*, **2007**, 25, 1171-6	44.5	253
69	Yeast surface display for protein engineering and characterization. *Current Opinion in Structural Biology*, **2007**, 17, 467-73	8.1	296
68	Theoretic criteria for antibody penetration into solid tumors and micrometastases. *Journal of Nuclear Medicine*, **2007**, 48, 995-9	8.9	95
67	Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. *Journal of Molecular Biology*, **2007**, 368, 1024-41	6.5	84
66	Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. *Structure*, **2006**, 14, 401-14	5.2	48
65	Contrasting secretory processing of simultaneously expressed heterologous proteins in Saccharomyces cerevisiae. *Biotechnology and Bioengineering*, **2006**, 93, 896-905	4.9	23
64	Improved mutants from directed evolution are biased to orthologous substitutions. *Protein Engineering, Design and Selection*, **2006**, 19, 245-53	1.9	53
63	A high affinity human antibody antagonist of P-selectin mediated rolling. *Biochemical and Biophysical Research Communications*, **2006**, 350, 508-13	3.4	6

62	Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. *Protein Expression and Purification*, **2006**, 48, 232-42	2	31
61	A flow cytometric assay for screening improved heterologous protein secretion in yeast. *Biotechnology Progress*, **2006**, 22, 1200-8	2.8	28
60	Stochastic kinetics of intracellular huntingtin aggregate formation. *Nature Chemical Biology*, **2006**, 2, 319-23	11.7	55
59	Isolating and engineering human antibodies using yeast surface display. *Nature Protocols*, **2006**, 1, 755-68	8.8	598
58	Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. *Protein Science*, **2006**, 15, 324-34	6.3	23
57	Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. *Proteins: Structure, Function and Bioinformatics*, **2006**, 62, 1026-35	4.2	56
56	Design criteria for engineering inorganic material-specific peptides. *Langmuir*, **2005**, 21, 6929-33	4	177
55	High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. *Biochemistry*, **2005**, 44, 10696-701	3.2	52
54	Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. *Nature Biotechnology*, **2005**, 23, 191-4	44.5	43
53	Directed evolution in chemical engineering. *AICHE Journal*, **2005**, 51, 3083-3085	3.6	
52	Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. *Acta Biomaterialia*, **2005**, 1, 145-54	10.8	51
51	Degradation of mutated bovine pancreatic trypsin inhibitor in the yeast vacuole suggests post-endoplasmic reticulum protein quality control. *Journal of Biological Chemistry*, **2004**, 279, 15289-97	5.4	55
50	Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17616-21	11.5	162
49	Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. *Protein Engineering, Design and Selection*, **2004**, 17, 293-304	1.9	113
48	Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. *Nucleic Acids Research*, **2004**, 32, e36	20.1	80
47	Single-chain antibody fragment-based adsorbent for the extracorporeal removal of beta2-microglobulin. *Kidney International*, **2004**, 65, 310-22	9.9	14
46	Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. *Journal of Immunological Methods*, **2004**, 287, 147-58	2.5	79
45	Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. *Journal of Biological Chemistry*, **2004**, 279, 30375-84	5.4	102

44	Engineering antibody affinity by yeast surface display. *Methods in Enzymology*, **2004**, 388, 348-58	1.7	107
43	Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. *Journal of Molecular Biology*, **2004**, 342, 539-50	6.5	113
42	Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. *Journal of Molecular Biology*, **2004**, 342, 901-12	6.5	89
41	Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor β Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect. *Molecular Pharmacology*, **2004**, 66, 864-869	4.3	38
40	Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. *Protein Engineering, Design and Selection*, **2003**, 16, 1081-7	1.9	43
39	Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. *Nature Biotechnology*, **2003**, 21, 163-70	44.5	403
38	Rapid method for measuring ScFv thermal stability by yeast surface display. *Biotechnology Progress*, **2003**, 19, 631-8	2.8	50
37	Rolling adhesion kinematics of yeast engineered to express selectins. *Biotechnology Progress*, **2003**, 19, 1033-7	2.8	7
36	Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. *Cancer Research*, **2003**, 63, 1288-96	10.1	130
35	Jay Bailey as mentor--the students Rperspective. *Biotechnology and Bioengineering*, **2002**, 79, 484-9	4.9	0
34	Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. *Biotechnology Progress*, **2002**, 18, 212-20	2.8	60
33	Protein engineering by cell-surface display. *Current Opinion in Biotechnology*, **2001**, 12, 395-9	11.4	167
32	Glutathione excretion in response to heterologous protein secretion in Saccharomyces cerevisiae. *Biotechnology and Bioengineering*, **2000**, 68, 389-95	4.9	12
31	Fine affinity discrimination by yeast surface display and flow cytometry. *Biotechnology Progress*, **2000**, 16, 31-7	2.8	124
30	Yeast surface display for directed evolution of protein expression, affinity, and stability. *Methods in Enzymology*, **2000**, 328, 430-44	1.7	242
29	Glutathione excretion in response to heterologous protein secretion in saccharomyces cerevisiae **2000**, 68, 389		1
28	A small-molecule catalyst of protein folding in vitro and in vivo. *Chemistry and Biology*, **1999**, 6, 871-9		72
27	Biosynthetic polypeptide libraries. *Current Opinion in Biotechnology*, **1999**, 10, 117-22	11.4	33

26	Phage on display. *Trends in Biotechnology*, **1999**, 17, 423-4	15.1	27
25	Expression of the 180-kD ribosome receptor induces membrane proliferation and increased secretory activity in yeast. *Journal of Cell Biology*, **1999**, 146, 273-84	7.3	47
24	Optimal screening of surface-displayed polypeptide libraries. *Biotechnology Progress*, **1998**, 14, 55-62	2.8	108
23	Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. *Nature Biotechnology*, **1998**, 16, 773-7	44.5	209
22	Leader peptide efficiency correlates with signal recognition particle dependence in Saccharomyces cerevisiae **1998**, 59, 286-293		14
21	Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant. *Journal of Molecular Recognition*, **1998**, 11, 10-3	2.6	11
20	Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. *Biochemistry*, **1998**, 37, 1264-73	3.2	75
19	Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control. *Journal of Biological Chemistry*, **1998**, 273, 19453-8	5.4	103
18	Yeast surface display for screening combinatorial polypeptide libraries. *Nature Biotechnology*, **1997**, 15, 553-7	44.5	1292
17	Expression level tuning for optimal heterologous protein secretion in Saccharomyces cerevisiae. *Biotechnology Progress*, **1997**, 13, 117-22	2.8	43
16	Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: II. *Biotechnology and Bioengineering*, **1996**, 52, 183	4.9	
15	Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: I. *Biotechnology and Bioengineering*, **1996**, 52, 1-2	4.9	2
14	An integrating vector for tunable, high copy, stable integration into the dispersed Ty delta sites of Saccharomyces cerevisiae. *Biotechnology Progress*, **1996**, 12, 16-21	2.8	86
13	Reduction of BiP levels decreases heterologous protein secretion in Saccharomyces cerevisiae. *Journal of Biological Chemistry*, **1996**, 271, 10017-22	5.4	72
12	Disulfide bond formation and eukaryotic secretory productivity. *Current Opinion in Biotechnology*, **1995**, 6, 203-8	11.4	33
11	Constitutive overexpression of secreted heterologous proteins decreases extractable BiP and protein disulfide isomerase levels in Saccharomyces cerevisiae. *Biotechnology Progress*, **1995**, 11, 171-7	2.8	41
10	Protein disulfide isomerase overexpression increases secretion of foreign proteins in Saccharomyces cerevisiae. *Bio/technology*, **1994**, 12, 381-4		159
9	Role of the Protein-Folding Chaperone BiP in Secretion of Foreign Proteins in Eukaryotic Cells. *ACS Symposium Series*, **1993**, 121-132	0.4	4

8	Stochastic stimulation of 2 mu multicopy plasmid amplification in yeast. *Biotechnology Progress*, **1993**, 9, 160-5	2.8	2
7	Mathematical modeling of a single-cell enzyme assay. *Biotechnology and Bioengineering*, **1990**, 35, 525-32	4.9	9
6	Propagation of an amplifiable recombinant plasmid in Saccharomyces cerevisiae: flow cytometry studies and segregated modeling. *Biotechnology and Bioengineering*, **1990**, 35, 565-77	4.9	17
5	A single-cell assay of beta-galactosidase activity in Saccharomyces cerevisiae. *Cytometry*, **1988**, 9, 394-404		40
4	A mathematical model of recombinational amplification of the 2 mu plasmid in the yeast Saccharomyces cerevisiae. *Journal of Theoretical Biology*, **1988**, 130, 481-92	2.3	5
3	Directed Evolution of Binding Proteins by Cell Surface Display: Analysis of the Screening Process111-126		1
2	Co-Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced-Humoral Immunity. *Advanced Therapeutics*,2100235	4.9	0
1	Intratumorally anchored cytokine therapy. *Expert Opinion on Drug Delivery*,1-8	8	1